Bank of New York Mellon’s Anixa Biosciences ANIX Stock Holding History

Bank of New York Mellon’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$133K	Hold	47,442	–	–	﹤0.01%	4182
2026 Q1	$122K	Sell	47,442 -10,829	-19%	-$32.1K	﹤0.01%	4079
2025 Q4	$182K	Hold	58,271	–	–	﹤0.01%	4053
2025 Q3	$192K	Hold	58,271	–	–	﹤0.01%	4029
2025 Q2	$192K	Sell	58,271 -474	-0.8%	-$1.35K	﹤0.01%	3996
2025 Q1	$168K	Sell	58,745 -1	-0%	-$3	﹤0.01%	3921
2024 Q4	$136K	Buy	58,746 +1	+0%	+$3	﹤0.01%	4006
2024 Q3	$185K	Sell	58,745 -14,305	-20%	-$44K	﹤0.01%	3931
2024 Q2	$161K	Sell	73,050 -14,000	-16%	-$39.7K	﹤0.01%	3983
2024 Q1	$272K	Sell	87,050 -9,604	-10%	-$38.3K	﹤0.01%	3820
2023 Q4	$375K	Buy	96,654 +57	+0.1%	+$192	﹤0.01%	3705
2023 Q3	$316K	Sell	96,597 -805	-0.8%	-$2.82K	﹤0.01%	3779
2023 Q2	$312K	Sell	97,402 -216	-0.2%	-$832	﹤0.01%	3812
2023 Q1	$420K	Hold	97,618	–	–	﹤0.01%	3578
2022 Q4	$415K	Sell	97,618 -238	-0.2%	-$1.15K	﹤0.01%	3642
2022 Q3	$481K	Hold	97,856	–	–	﹤0.01%	3583
2022 Q2	$299K	Sell	97,856 -796	-0.8%	-$2.51K	﹤0.01%	3879
2022 Q1	$271K	Hold	98,652	–	–	﹤0.01%	4071
2021 Q4	$293K	Hold	98,652	–	–	﹤0.01%	4100
2021 Q3	$471K	Buy	98,652 +55,350	+128%	+$250K	﹤0.01%	3847
2021 Q2	$168K	Sell	43,302 -7,640	-15%	-$32.5K	﹤0.01%	4133
2021 Q1	$238K	Sell	50,942 -1,027	-2%	-$4.91K	﹤0.01%	3993
2020 Q4	$160K	Buy	51,969 +12,588	+32%	+$31.6K	﹤0.01%	4020
2020 Q3	$96K	Hold	39,381	–	–	﹤0.01%	3958
2020 Q2	$121K	Hold	39,381	–	–	﹤0.01%	3887
2020 Q1	$63K	Sell	39,381 -1,581	-4%	-$4.63K	﹤0.01%	3935
2019 Q4	$134K	Buy	40,962 +1,204	+3%	+$4.42K	﹤0.01%	3984
2019 Q3	$159K	Hold	39,758	–	–	﹤0.01%	3947
2019 Q2	$144K	Sell	39,758 -49	-0.1%	-$207	﹤0.01%	3978
2019 Q1	$180K	Sell	39,807 -3,172	-7%	-$15.1K	﹤0.01%	3906
2018 Q4	$169K	Buy	42,979 +1,069	+3%	+$4.59K	﹤0.01%	3879
2018 Q3	$194K	Sell	41,910 -1,646	-4%	-$6.2K	﹤0.01%	3943
2018 Q2	$132K	Sell	43,556 -2,923	-6%	-$10.8K	﹤0.01%	3967
2018 Q1	$178K	Buy	46,479 +1,230	+3%	+$4.73K	﹤0.01%	3954
2017 Q4	$107K	Buy	+45,249	New	+$117K	﹤0.01%	4082

Other funds holding ANIX

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

GAM

Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return

Bank of New York Mellon's ANIX Position: Q2 2026 in Review

Bank of New York Mellon held its Anixa Biosciences (ANIX) position steady in Q2 2026 at 47,442 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #4182.

Bank of New York Mellon first reported a position in ANIX in Q4 2017 and has held it in 35 quarters since. The position peaked at $481K in Q3 2022. 30 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

Bank of New York Mellon held 47,442 shares of Anixa Biosciences worth $133K as of Q2 2026.
Bank of New York Mellon left its Anixa Biosciences share count unchanged in Q2 2026.
Anixa Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4182 holding.
Bank of New York Mellon first reported a position in Anixa Biosciences in Q4 2017 and has held it in 35 quarters since.
Bank of New York Mellon's Anixa Biosciences position peaked at $481K in Q3 2022.
30 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.